Results of three midstage trials demonstrate the efficacy of Novartis' secukinumab, or AIN457, in improving symptoms of patients with moderate to severe plaque psoriasis. Secukinumab is a human monoclonal antibody designed to target interleukin-17A, a cytokine associated with immune-mediated illnesses.
Alcon, a subsidiary of Novartis, received a subpoena from HHS as part of a civil investigation into possible health care fraud. The agency is seeking documents related to marketing of several medical products, including eye drug Vigamox, as well as payment to clinicians.
South Korea's Fair Trade Commission ordered GlaxoSmithKline to pay $2.6 million for anti-competitive behavior related to a marketing agreement with local drugmaker Dong-A Pharmaceutical. In 2000, GSK asked Dong-A to stop selling generic Zofran in exchange for exclusive rights to the nausea drug's branded form and antiviral Valtrex, the commission said.
The Federal Trade Commission reported 28 patent settlements that delayed the launch of generic medicines during the fiscal year that ended Sept. 30. FTC Chairman Jon Leibowitz called on the congressional deficit-reduction supercommittee to support legislation that would ban such agreements.
BioProgress signed an agreement for exclusive rights to distribute its drug-delivering strips and capsules in China and Taiwan through AXM Pharma. BioProgress owns the Soluleaves technology that delivers vitamins and drugs through cellulose-based capsules and film strips that dissolve in the mouth.